MET and liver cancer: Mechanistically, MET repressed liver cancer immunogenicity independent of the traditional PI3K–AKT cascade, and MET interacted with vacuolar ATP synthase (V-ATPase) and mediated the activation of mammalian target of rapamycin (MTOR), thus suppressing liver cancer immunogenicity.